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Summary Between July 1990 and September 1993, 32 patients with locally advanced irresectable adenocarcinoma of the pancreas,
histologically proven by laparotomy, were involved in our study. Patients were treated with hyperfractionated, accelerated radiotherapy and
simultaneous application of 5-fluorouracil and folinic acid. Chemotherapy was given on days 1,2 and 3. Determination of the target volume for
radiotherapy was carried out by computerized axial tomography. The total tumour dose of 44.8 Gy was applied relative to the 90% isodose in
two daily fractions of 1.6 Gy, resulting in ten fractions per week. On the first three days of radiotherapy, 600 mg m- of 5-fluorouracil and 300
mg m-3 of folinic acid were given i.v. According to response, chemotherapy was repeated in 4-week intervals. The median survival time for all
patients was 12.7 months, compared with 3-7 months after palliative surgery (historical control). The median progression-free interval was
6.6 months. Toxicity and therapy-induced morbidity were recorded according to WHO criteria. Nausea and vomiting of WHO grade and 11
occurred in 72.1% and of grade IlIl and IV in 27.9% of the patients. WHO grade and 11 diarrhoea was seen in 11 patients. The overall
incidence of leucopenia and thrombocytopenia was 37.4%; severe side-effects (WHO III-IV) occurred in 9.3% of all patients. One patient
experienced a severe mucositis (WHO 1II). This combined modality treatment consisting of accelerated hyperfractionated radiotherapy and
chemotherapy turned out to be feasible for patients with locally advanced, irresectable pancreatic cancer. The therapy could be applied in a
short period of time, approximately half the time used in conventional therapy schemes.
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In Central Europe and North America, the incidence ofcarcinoma
of the pancreas is 6-10 per 100 000 inhabitants (Brennan et al,
1989; Conrath, 1986 and 1987), amounting to about 5% of all
diagnosed tumours. Incidence only slightly exceeds mortality, as
almost all patients suffering from pancreas carcinoma finally die
from tumour-related causes. More than 90% of all malignant
tumours ofthe pancreas are adenocarcinomas (Cubilla et al, 1978).
Sixty to seventy per cent are localized in the head, about 15% in
the body and 10% in the tail of the pancreas; in the remaining
cases an exact localization is impossible (Cubilla et al, 1979).
Surgery is the only curative treatment modality and, unfortunately,
at the time of diagnosis most tumours have already advanced and
80% are already inoperable. For these patients, the prognosis is
unfavourable with a median survival time of 4-6 months (Brennan
et al, 1989). The median survival time of patients with pancreatic
carcinoma who undergo palliative surgical treatment (bypass
implantation) is 3-7 months (Brennan et al, 1989; De Rooij et al,
1991). Radiotherapy is frequently applied as a palliative treatment
over a period of several weeks to prolong median survival time
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while maintaining an acceptable quality of life (Dobelbower and
Bronn, 1990).
Many antineoplastic agents have been tested forthe treatment of
pancreatic carcinoma. With a response rate ofapproximately 20%,
5-fluorouracil (5-FU) has turned out to be one of the most active
agents against this tumour entity (Brennan et al, 1989; Decarpio et
al, 1989; Arbuck, 1990; Bronn et al, 1995; Isacoffet al, 1995).
In 1981, the Gastrointestinal Study Group (GITSG) published
the findings of a randomized trial comparing a combination ofa 5-
FU bolus (500 mg m-2 on the first 3 days ofeach 20-Gy course), in
a split-course technique, and radiotherapy, using total doses of
40 and 60 Gy with radiotherapy alone. After the completion of
radiotherapy, chemotherapy was continued for 2 years or until
progression occurred. The combined treatment scheme showed
significantly better results than the radiotherapy arm alone. Forty
per cent of the patients treated with combined modality therapy
were alive after 1 year compared with 10% of the radiotherapy-
only group, but there were no significant differences between 40
and 60 Gy in the combined therapy groups (GITSG, 1981). In all
these studies, 5-FU, as a proposed radiosensitizer, was applied
simultaneously to radiotherapy.
The rationale for our study (44.8 Gy hyperfractionated and 300
mg folinic acid per m2 body surface plus 600 mg 5-FU per m2 body
surface on days 1-3 ofthe radiotherapy) werethebetterresults ofthe
combined treatment modalities vs radiotherapy alone. Modulated 5-
FU was chosenbecause ofits enhanced activity comparedwith5-FU
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Table 1 Patient characteristics Inclusion and exclusion criteria
n=32
Women 11, Men 21
median age 62.3 years
range 46.2-78.7 years
4 Isodoses
o90
80
60
40
30
20
J Pointdoses
X Y Value
0.0 0.0 96
-6.6 -7.1 10
8.2 -5.7 10
0.8 -6.5 27
Figure 1 Radiation scheme with a three field arrangement
alone, proven in the treatment of adenocarcinomas of the colon
(Machover et al, 1982).
The main positive effect ofaccelerated hyperfractionation is the
time-saving effect in this palliative situation. It is doubtful ifthere
is a higher biological effect of the accelerated hyperfractionation
in pancreatic carcinoma because other studies show no influence
of the proliferation rate and grading on the overall survival
(Tannapfel et al, 1992). Single-dose escalation in the GITSG study
showed no increase in overall survival. Concerning the dose and
time schedule for the chemotherapy application, we followed the
example ofthe GITSG very closely.
PATIENTS AND METHODS
From July 1990 to September 1993, a total of 32 patients with
locally advanced irresectable pancreatic carcinoma, histologically
proven by laparotomy and without distant metastases, were
involved in a cooperative feasibility study. Therapy consisted of
hyperfractionated, accelerated radiotherapy of 44.8 Gy over a
three to four field arrangement with daily fractional doses of 2 x
1.6 Gy and 5-FU and folinic acid i.v. on days 1-3. Chemotherapy
was repeated at 4-week intervals until disease progression.
Patient characteristics
A total of 32 patients (1 women and 21 men) were treated in this
study. The median age ofthe patients was 62.3 years (Table 1). In
all patients, the irresectability ofthe tumour was proven by laparo-
tomy with histological confirmation ofthe diagnosis.
Histological examination after laparotomy yielded the diagnosis
of adenocarcinoma of the pancreas in all cases; in 30 patients, the
tumour was localized in the head of the pancreas and in two
patients, in the body. All patients had a tumour stage T2 or T3
according to the TNM classification.
Tumours showed a high degree of differentiation (GI) in four
patients, a medium degree (G2) in seven patients and a low degree
(G3) in 11 patients; the tumour was anaplastic (G4) in one patient. In
nine patients, nograding wasestablished bythe examining pathologist.
All patients with a histologically confirmed, locally advanced
and irresectable adenocarcinoma of the pancreas were included in
this study. Irresectability was proven by explorative laparotomy.
Additionally, only patients with a WHO performance status <2 and
age < 80 years with normal cardiac, hepatic, renal andbone marrow
function were enrolled for the study after the patients' informed
consent. Patients with secondary malignancies, metastatic disease,
pregnancy or contraindications against 5-FU or folinic acid were
excluded from the study.
Therapy
Determination of the target volume for radiotherapy was carried
out either by identification of the macroscopically visible tumour
size on computerized axial tomography including a 2-cm safety
margin or by intraoperative clip marking plus a 2-cm safety
margin. The total dose was 44.8 Gy to the 90% isodose in 28 frac-
tions of 1.6Gy each applied in two fractions aday with a 6-h break.
The field size was between 9 x 10 cm and 10 x 11cm for the ante-
riorfields andbetween 8 x 9 cm and 9 x 10 cm forthe lateral fields.
Treatment was administered ten times a week so that the radio-
therapy was finished within less than 3 weeks. All patients were
treated using an isocentric box technique with three or four fields.
All radiation fields were irradiated daily. Treatment was carried
out on a linear accelerator using X-rays with an energy of 10 MeV
(Figure 1).
Chemotherapy was given i.v., consisting of folinic acid in a
dosage of300 mg m-2 via a 10 min short infusion, followed 50 min
later by the application of5-fluorouracil in adosage of600 mg m-2
as a 10 min short infusion. This therapy was repeated on day 28 in
case ofno disease progression.
Staging and follow-up
No systematic lymph node sampling was carried out. The staging
examinations consisted of computerized tomography (CT) scans
of the abdomen, liver ultrasound, chest radiograph and bone scan.
Examinations during follow-up consisted ofphysical examination,
weekly blood counts and ultrasound of the abdomen, alternating
with CT scans. These examinations were carried out before the
start of therapy and 4 weeks after the end of therapy. Afterwards,
they were repeated every 3 months.
RESULTS
Identifying objective response following treatment of localized
pancreatic cancer is difficult. This analysis was carried out in
terms of disease progression-free interval, overall survival, toxi-
city, side-effects of therapy and states of body weight and pain
relief. The median observation time was 14.2 months (range
2.2-42 months).
Progression free interval
The disease progression-free interval was calculated from the
start of therapy. Most of the patients with recurrences showed an
initial decrease of the performance status. Criteria of tumour
progression were the growth ofthe pancreatic tumour, detected by
CT scans and ultrasound, the detection ofdistant metastases or the
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Figure 2 Kaplan-Meier assessment of disease progression-free interval
(n=32)
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Table 2 Frequency of therapy-associated side-effects (%)
WHO grade
Nausea and vomiting (100%) Grade 1-2 n=23 (72.1%)
Grade 3 n=7 (21.9%)
Grade 4 n=2 (6.0%)
Diarrhoea (34.3%) Grade 1 n=4 (12.5%)
Grade 2 n=7 (21.8%)
Mucositis (9.3%) Grade 2-3 n=3 (9.3%)
Leukocytopenia/thrombocyctopenia (37.4%) Grade 1 n=5 (15.6%)
Grade 2 n=4 (12.5%)
Grade 3-4 n=3 (9.3%)
Sepsis n=2 (6.3%)
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Figure 3 Kaplan-Meier assessment of total survival and survival with tumour
progress.-, Overall survival (n = 32);---, Survival with disease progression.
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occurrence of ascites. According to these criteria, tumour progres-
sion could be detected in eight patients.
In three patients, no signs of recurrence were observed at this
time of the observation period. The Kaplan-Meier assessment
showed a median progression-free interval of 6.6 months for all
patients (Figure 2).
Survival
In all patients, the first day of radiochemotherapy was chosen as
the starting point for survival analysis. The median survival time,
according to Kaplan-Meier, was 12.7 months. The 1-year survival
rate amounted to 53.1% and the 2-year survival rate, 11.7%. Figure
3 shows the overall survival of all patients and the survival for
patients with progressive disease (median 3.4 months). So far,
one patient has survived for 42 months without any sign of recur-
rence; five patients have survived longer than 20 months.
Side-effects
The median number of chemotherapy cycles per patient was
seven (range 2-17). Slight nausea and vomiting (WHO I-II) was
seen in 72.1% of the patients, severe sickness (WHO III-IV)
in 27.9%. Two patients suffering from nausea and vomiting
(WHO IV) showed tumour progression with infiltration of the
stomach and duodenum. Moderate diarrhoea (WHO I-II) was
observed in 34.3% of the patients. Mucositis (WHO Il-III)
occurred in 9.3%. Of the total, 37.4% of the patients showed a
leucopenia and thrombocytopenia.
Figure 4 Development of body weight (%)
In four patients, the scheduled chemotherapy had to be delayed
because of haematological toxicity resulting in leucopenia or
thrombocytopenia. A dose reduction of50% was required because
of leucopenia in two patients and mucositis in three patients.
Severe leucopenia and thrombocytopenia (WHO III-IV) were
seen in 9.3% of the patients. Of these, 6.3% patients developed a
sepsis (Table 2).
Body weight and pain
For the assessment of changes in body weight, the weight 3
months before beginning of therapy was chosen as a reference
parameter, provided it was known to the patient. The weight values
were recorded in monthly intervals. During combined treatment,
there was an additional loss of weight with an average of 3.9 kg,
ranging from 0.9-7.6 kg compared with the weight at the start of
therapy. This difference was shown to be highly significant (P <
0.001). The mean relative weight loss was 5.9%, ranging from
1.4-13.0% (Figure 4).
Figure 4 shows that the first month after the onset of therapy
proves to be very strenuous for the patients. But once this phase
has been finished, there is no additional loss ofbody weight in the
course of the following weeks. Afterwards, the medium value
shows a constant development for a period oftime up to 12 months
after therapy.
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Figure 5 Pain development and need of analgetics. --.--, 0 = Pain free
-{}, 1 = pain free with non-opoids; - - - - -, 2 = pain free with opoids;
curve 0 + curve 1
The influence of this therapy on pain, the development of pain,
and the application of analgetics were measured and analysed
using a questionnaire with daily patients' statements about their
analgesic consumption and pain status.
The rate of patients not requiring analgetics decreased from
34% at the beginning of therapy to below 20% under therapy.
However, this rate increased again after therapy, reaching a
maximum value of 80% at 7-9 months after the end of therapy
(Figure 5).
DISCUSSION
In patients with adenocarcinoma of the pancreas treated by cura-
tive surgery, median survival time ranges from 9 to 18 months.
However, 5-year survival rates between 0% and 37% have been
observed (Russel, 1990) after curative surgery. After palliative
surgery, median survival time is only 3-7 months (Brennan et al,
1989; De Rooij et al, 1991). Median survival time for patients
with locally irresectable pancreatic carcinoma reported in radio-
oncological literature, using varying therapy schedules for radio-
chemotherapy, ranges from 7.5 to 16.5 months (Tepper et al, 1987,
1991; Wagener et al, 1989; Seydel et al, 1990; Shibamoto et al,
1990; Boz et al, 1991; Jeekel et al, 1991; Montemaggi et al, 1991;
Ardalan et al, 1994; Whittington et al, 1995; Table 3).
Our patients had a median survival time of 12.7 months.
Seventy-five per cent ofall patients were alive at 6 months, 10% at
18 months, and 5% at 2 years after therapy. These are only average
results compared with other trials, but we were able to achieve
them with a shortened treatment time ofonly 3 weeks, while treat-
ment time in other studies usually ranges from 6 to 10 weeks. The
combined modality treatment used in our study improved median
survival time of the patients more than twice compared with
historical patient collectives who underwent palliative surgery or
no surgical treatment. (Wagener et al, 1994).
The Amsterdam group, who also applied hyperfractionated,
accelerated radiotherapy, reported a 45% rate of severe side-
effects, but no occurrence of grade IV side-effects (Schuster et al,
1986). Compared with our study, the dosages used in their study
were partially hyperfractioned and considerably higher, but
without chemotherapy. The Dutch group reported the occurrence
ofgrade I and II diarrhoea in 25% ofall patients, while the GITSG
study (GITSG, 1981) yielded a total rate of diarrhoea of 6%
without stating WHO grades. The GITSG study classified nausea
and vomiting into grades 'slight to medium' and 'severe'. Thirty-
four per cent ofall patients suffered from slight to medium and 5%
Table 3 Median survival times after chemoradiotherapy: survey of literature
Reference Combined modality Median survival
(months)
Whittington et al (1995) 5-FU + 59.4 Gy 11.9
Ardalan et al (1994) 5-FU + PALA + 59.4 Gy 12.5
Jeekel et al (1991) 5-FU + 50 Gy 10
Boz et al (1991) 5-FU + cisplatinum + 60 Gy 7.5
Seydel et al (1990) 5-FU + 40.8 Gy hyperfractionated 9
+ boost
Wagener et al (1989) FAP + 5-FU + 40 Gy 14
Tepper et al (1987) Pre- and post-operative irradiation 16.5
+ IORT + CTX
from severe side-effects. The GITSG found no severe vomiting in
the 60-Gy group without chemotherapy, compared with 4% in the
60 Gy plus 5-FU group, slight to medium grade vomiting in 28%
compared with 34% and no occurrence of diarrhoea compared
with 7%. From these data, it can be concluded that the combined
therapy only causes a slight overall increase of toxicity in the
gastrointestinal tract.
In our own study, nine patients (27.9%) had grade III-IV nausea
and vomiting. In 11 patients (34.3%), grade I and II diarrhoea was
observed. Leucopenia and thrombocytopenia occurred in 12
patients (37.4%). Two patients developed septicaemia, which did
not lead to therapy-induced death. Mucositis g'rade II-III was seen
in a total ofthree patients (9.3%) (Figure 4). This low number may
be owing to the low dose of 5-FU compared with other studies,
where higher doses lead to an increase of mucositis seen in up to
80% ofthe patients (Creaven et al, 1989).
Loss of weight during antineoplastic therapy is one of the most
frequent symptoms in patients with pancreatic carcinoma. Two
study groups give absolute and one relative figures; all of which
are given as average values (Schuster et al, 1986; Dobelbower et
al, 1990; Whittington et al, 1995); loss ofweight is limited to dura-
tion of treatment. For the patients examined in our study, the loss
of weight is limited to the time of 4 weeks after the onset of
therapy, i.e. approximately 1.5 weeks after the end oftherapy. The
medium weight loss of all patients in our study amounted to 3.9
kg, which is similar to other studies (Whittington et al, 1995).
CONCLUSION
We were able to show that the chosen combined modality treat-
ment is feasible and only induces acceptable and manageable
toxicity in patients with locally advanced, irresectable adeno-
carcinoma of the pancreas. Median disease progression-free
interval and median survival times can be compared with the
results of other publications. Treatment time, which plays an
important role for these patients with a poor prognosis could be
reduced compared with other studies. These results have to be
confirmed by further studies including more patients.
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